Abstract
This study aimed to investigate whether the use of molecular-targeted agents could affect gastrointestinal (GI) toxicity in palliative radiotherapy (RT) for metastatic bone tumors in the abdominopelvic region. We collected data of patients who received palliative RT for bone metastases in the abdominopelvic region between 2013 and 2014 from six institutions. Data of 395 patients were collected and184 patients received molecularly targeted therapy, of whom 80 received vascular endothelial growth factor (VEGF)-targeted agents. For 556 lesions, 410 sessions of irradiation were undergone. GI toxicity of ≥G3 was observed in 3.8% of patients. The incidence rates of ≥G3 GI toxicity in patients without targeted agents use, in those using VEGF-targeted agents and in those using non-VEGF-targeted agents were 3.8, 7.5 and 1.0%, respectively. Regarding risk factors of the occurrence of ≥G3 GI toxicity, univariate analysis in all patients showed that a history of abdominopelvic surgery was a significant risk factor (P = 0.01), and the use of VEGF-targeted agents showed a trend of high incidence (P = 0.06). In patients using VEGF-targeted agents, both univariate and multivariate analysis showed that combined anticoagulant use (P = 0.03 and 0.01) and agent use between 1 week before and after RT (P = 0.046 and 0.03) were significant risk factors. In conclusion, the history of abdominopelvic surgery was associated with ≥G3 GI toxicity and the use of VEGF-targeted agents showed a trend for high incidence. When using VEGF-targeted agents, caution should be exercised in the combined use of anticoagulants and in the agent use between 1 week before and after RT.
Highlights
Molecular-targeted agents are drugs that block the growth of cancer cells by interfering with specific targeted molecules and they play an essential role in current cancer treatment
We investigated whether the use of moleculartargeted agents could affect gastrointestinal (GI) toxicity in palliative RT for metastatic bone tumors in the abdominopelvic region, where the gastrointestinal tract was included in the radiation beam pathway
In patients using vascular endothelial growth factor (VEGF)-targeted agents, both univariate and multivariate analysis showed that combined anticoagulant use (P = 0.03 and 0.01, respectively) and agent use between 1 week before and after RT (P = 0.046 and 0.03, respectively) were significant risk factors
Summary
Molecular-targeted agents are drugs that block the growth of cancer cells by interfering with specific targeted molecules and they play an essential role in current cancer treatment. As molecular-targeted agents act on cancer cells at the beginning of development, they were expected to reduce toxicities compared with conventional 629. Severe toxicities have recently emerged, such as interstitial lung disease due to epidermal growth factor receptor-tyrosine kinase inhibitors [1] and bleeding or perforation events due to vascular endothelial growth factor (VEGF)targeted agents [2]. Patients with bone metastases often receive palliative radiotherapy (RT) for pain relief, prevention of spinal cord paralysis or prevention of fracture. We often encounter the situation where patients need to receive palliative RT for bone metastases at the time as using molecular-targeted agents. The safety of the combination of palliative RT and molecularly targeted therapy is not well known
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
